AbbVie Hold Rating: Balancing Growth Opportunities with Valuation and Pipeline Challenges

Bank of America Securities analyst Jason Gerberry has reiterated their neutral stance on ABBV stock, giving a Hold rating on December 9.

Jason Gerberry has given his Hold rating due to a combination of factors that present both opportunities and challenges for AbbVie. On the positive side, the company has a relatively stable growth outlook with limited loss of exclusivity, positioning it well within its peer group. However, this is offset by a premium valuation and a lack of significant late-stage pipeline catalysts, which limits the stock’s upside potential.
Gerberry also highlights the balanced risk-reward scenario for AbbVie’s core immunology brands, Skyrizi and Rinvoq, as well as the potential for an aesthetics market rebound. While there is some optimism for Rinvoq’s growth through indication expansion, Skyrizi faces competitive pressures. Additionally, the aesthetics segment, particularly the new Botox launch, may not achieve the company’s ambitious sales targets due to weakening consumer demand for dermal fillers. Overall, these factors contribute to the Hold rating as the stock’s growth prospects are tempered by these challenges.

Gerberry covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Jazz Pharmaceuticals, and Arcellx Inc. According to TipRanks, Gerberry has an average return of 14.7% and a 60.08% success rate on recommended stocks.

In another report released on December 9, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $241.00 price target.